Hannah C Karpel

14PUBLICATIONS
72CO-AUTHORS
Predictive and prognostic markersWomen's studies (incl. girls' studies)Cancer therapy (excl. chemotherapy and radiation therapy)Epigenetics (incl. genome methylation and epigenomics)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Jul 10, 2026
Endometrial Cancer by ERBB2 Amplification (ERBB2amp) Status: Differences in Molecular Subtypes, Ancestry, and Real-World Outcomes.

|Mar 11, 2025
The missing data: A review of gender and sex disparities in research.

Hannah C Karpel, Linda M Zambrano Guevara, B J Rimel

|Dec 05, 2024
Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials.

Hailei Zhang, Anna Rutkowska, Antonio González-Martín

|Oct 16, 2024
Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors.

Brian M Slomovitz, David Cibula, Weiguo Lv

|Sep 25, 2024
Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial.

Giorgio Valabrega, Matthew A Powell, Sakari Hietanen

|Jul 01, 2024
Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study.

Whitney S Graybill, Beatriz Pardo Búrdalo, David M O'Malley

Pageof 3

Frequent Collaborators

6 joint publications

Bradley J Monk

5 joint publications

Mansoor Raza Mirza

3 joint publications

Robert L Coleman

3 joint publications

Antonio González-Martin